Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | AMPD2 | Q01433 | 1/20 | 0.41 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4987928 | 0.89 | TNF (0.44) | DRD4DRD2 | |
| SCHEMBL4985028 | 0.88 | KDM4E (0.45) | DRD2GRM2OPRM1 | |
| SCHEMBL4993145 | 0.88 | FAAH (0.47) | GRM2 | |
| SCHEMBL4986723 | 0.87 | KDM4E (0.46) | L3MBTL1OPRM1 | |
| SCHEMBL4985480 | 0.86 | FAAH (0.43) | DRD2CHRM3GRM2L3MBTL1 | |
| SCHEMBL4985987 | 0.86 | KDM4E (0.44) | DRD4GPR52GRM2 | |
| SCHEMBL4988838 | 0.85 | GRM2 (0.47) | DRD2GRM2 | |
| SCHEMBL4986124 | 0.83 | CLPP (0.42) | GRM2 | |
| SCHEMBL4993338 | 0.83 | CLPP (0.42) | GRM2OPRM1 | |
| SCHEMBL4986167 | 0.83 | GRM2 (0.41) | DRD4GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | DRD4 3767/4885DRD2 3142/4885AMPD2 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.